Word: eschenbach
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...three-year health-policy dispute when it approved the "morning-after pill," Plan B, for over-the-counter sale yesterday. But fallout from the political feud surrounding Plan B will play out for months. Democratic Senators Patty Murray and Hillary Clinton dropped their objections Thursday to confirming Andrew von Eschenbach, acting FDA commissioner since September 2005; the Senators had vowed to stall von Eschenbach's nomination at the committee stage until the emergency contraception was made available over the counter. But more bitter response erupted immediately from conservative and faith-based groups, some calling on President Bush to withdraw...
NOMINATED. ANDREW VON ESCHENBACH, 64, as George W. Bush's third Food and Drug Administration (FDA) commissioner; in Washington. The promotion of Von Eschenbach, who has been acting FDA chief since the resignation of Lester Crawford last September, promptly stalled over the controversy surrounding Plan B, the "morning after" pill. A urology surgeon who has led the National Cancer Institute since 2002 (he now plans to retire from that job), Von Eschenbach enters a long-simmering battle. The Bush Administration has so far delayed a decision on whether to approve the emergency contraceptive pill for over-the-counter use despite...
...Administration moved swiftly to name Dr. Andrew von Eschenbach as interim FDA chief after the September departure of Commissioner Lester Crawford just two months after his confirmation. (The Senate is investigating a possible failure to disclose financial interests.) Von Eschenbach, a Texas urologist with close ties to the Bush family, has no regulatory experience. Plus, he's already fully engaged. He has headed the National Cancer Institute (NCI) since 2002. The plan: have him do both jobs...
...where the new chief sees synergy, others see conflict of interest. NCI supports research on treatments reviewed by the FDA. "How can you wear both hats and be true to the missions of both organizations?" asks Merrill Goozner of the Center for Science in the Public Interest. Von Eschenbach also sits on the board of a nonprofit cancer advocacy group called C-Change--along with execs from major drug firms...
Such concerns led to the Administration's own Plan B. While remaining at NCI, von Eschenbach will turn over day-to-day management to deputy Dr. John Niederhuber. The acting FDA chief also reassured his staff that he "will not participate in certain FDA matters in which NCI is a party"--unless requested. --By Claudia Wallis and Eric Roston